feed
view company updates
tools
perform investment research
network
join events & discussions
advisory
about us
Redeye Capital
Alligator Bioscience: 900mg reached with ATOR-1017
Research Note
2022-09-30
11:42
Redeye comments on Alligator’s successful conclusion of the phase I trial with ATOR-1017.
RR
Richard Ramanius
Sign up for free to continue
Sign up with Email
Sign in with Google
Already a member?
Sign in
Disclosures and disclaimers
Premium Plan required to unlock
Unlock companies to access
more high quality research.
View Plans